FrancophonIA/ELRC3.0 huggingface dataset:
English: Exviera contains lactose
Slovenian: Zdravilo Exviera vsebuje laktozo
English: Genotype 1a, with compensated cirrhosis dasabuvir + ombitasvir/paritaprevir/ritonavir + ribavirin*
Slovenian: 12 tednov genotip 1a, s kompenzirano cirozo dasabuvir + ombitasvir/paritaprevir/ritonavir + ribavirin*
English: In genotype 1b, substitutions C316N, C316Y, M414T, Y448H, and S556G in HCV NS5B reduced susceptibility to dasabuvir.
Slovenian: M414T, Y448H in S556G v NS5B HCV zmanjšale občutljivost za dasabuvir.
English: Concomitant use is contraindicated (see
Slovenian: Sočasna uporaba je kontraindicirana (glejte poglavje
English: ↑ darunavir ↓ dasabuvir ombitasvir paritaprevir lopinavir / ritonavir 400/100 mg dasabu vir + ombitas vir/parit lopinavir
Slovenian: ↑ darunavir ↓ dasabuvir ↔ ombitasvir ↓ paritaprevir lopinavir / ritonavir 400/100 mg dvakrat na dan1 Mehanizem:
English: Sirolimus 2 mg was dosed alone, 0.5 mg administered with dasabuvir + ombitasvir/paritaprevir/ritonavir.
Slovenian: Sirolimus 2 mg je bil uporabljen samostojno, odmerek 0,5 mg pa skupaj z dasabuvirjem + kombinacijo ombitasvir/paritaprevir/ritonavir.
English: GT1b dasabuvir and ombitasvir/paritaprevir/ritonavir (8 weeks)
Slovenian: GT1b dasabuvir in ombitasvir/paritaprevir/ritonavir (8 tednov)
English: MUSCLE RELAXANTS Carisoprodol
Slovenian: MIŠIČNI RELAKSANTI
English: Tacrolimus 2 mg single dose7
Slovenian: AUC Ctrough Klinične opombe takrolimus Posamezen odmerek 2 mg 7
English: Cross-resistance is expected among NS5A inhibitors, NS3/4A protease inhibitors, and non-nucleoside NS5B inhibitors by class.
Slovenian: NS3/4A in nenukleozidnimi zaviralci NS5B.
English: Film-coating
Slovenian: Filmska obloga:
English: Adverse reactions identified with dasabuvir in combination with ombitasvir/paritaprevir/ritonavir or ombitasvir/paritaprevir/ritonavir and ribavirin
Slovenian: Preglednica 3: Neželeni učinki ugotovljeni z dasabuvirjem v kombinaciji z ombitasvir/paritaprevir/ritonavir ali z ombitasvir/paritaprevir/ritonavir in ribavirinom
English: GT1b dasabuvir and ombitasvir/paritaprevir/ritonavir (12 weeks)
Slovenian: GT1b dasabuvir in ombitasvir/paritaprevir/ritonavir (12 tednov)
English: Emtricitabine/ tenofovir 200 mg once daily/300 mg once daily dasabu vir + ombitas vir/parit aprevir/ ritonavi r
Slovenian: 200 mg enkrat na dan/300 mg enkrat na dan dasabuvir ombitasvir/ paritaprevi r/ritonavir emtricitabin
English: 250 mg single dose
Slovenian: karisoprodol Posamezen odmerek 250 mg
English: Dasabuvir must always be administered together with ombitasvir/paritaprevir/ritonavir .
Slovenian: Dasabuvir je treba vedno uporabiti skupaj z ombitasvirjem/paritaprevirjem/ritonavirjem.
English: Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin; therefore, ribavirin is contraindicated in women who are pregnant and in the male partners of women who are pregnant.
Slovenian: Pri vseh živalskih vrstah, izpostavljenih ribavirinu, so ugotovili teratogene in/ali embriocidne učinke.
English: HCV Genotype 1b dasabuvir and ombitasvir/paritaprevir/ritonavir
Slovenian: HCV Genotip 1b dasabuvir in ombitasvir/paritaprevir/ritonavir
English: ANTIMYCOBACTERIALS Rifampicin
Slovenian: ZDRAVILA Z DELOVANJEM NA BAKTERIJO MYCOBACTERIUM TUBERCULOSIS rifampicin
English: Arm B: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV (24 weeks)
Slovenian: Skupina B: dasabuvir in ombitasvir/paritaprevir/ritonavir + RBV (24 tednov)
English: Arm A: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV
Slovenian: Skupina A: dasabuvir in ombitasvir/paritaprevir/ritonavir + RBV
English: Treated subjects (N=394) had a median age of 54 years (range: 19 to 71); 49.0% were prior pegIFN/RBV null responders; 21.8/% were prior pegIFN/RBV partial responders; and 29.2% were prior pegIFN/RBV relapsers; 57.6% were male; 8.1% were Black; 20.6% had a history of depression or bipolar disorder; 87.1% had baseline HCV RNA levels of at least 800,000 IU per mL; 17.8% had portal fibrosis (F2) and 14.5% had bridging fibrosis (F3); 58.4% had HCV genotype 1a infection; 41.4% had HCV genotype 1b infection.
Slovenian: Zdravljeni preiskovanci (N = 394) so bili mediano stari 54 let (razpon: od 19 do 71); 49,0 % jih predhodno ni imelo odziva na pegIFN/RBV; 21,8 % jih je predhodno imelo delen odziv na pegIFN/RBV in 29,2 % jih je predhodno imelo recidiv ob pegIFN/RBV; 57,6 % je bilo moških; 8,1 % je bilo črncev; 20,6 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 87,1 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj 800.000 i. e./ml; 17,8 % jih je imelo portalno fibrozo (F2) in 14,5 % jih je imelo fibrozo z mostiči (F3); 58,4 % jih je imelo okužbo s HCV genotipa 1a; 41,4 % jih je imelo okužbo s HCV genotipa 1b.
English: dasabuvir and ombitasvir/paritaprevir /ritonavir + ribavirin
Slovenian: dasabuvir in ombitasvir/paritaprevir /ritonavir + ribavirin
English: Treated subjects (N=179) had a median age of 57 years (range: 26 to 70); 35.2% were prior pegIFN/RBV null responders; 28.5% were prior pegIFN/RBV partial responders; and 36.3% were prior pegIFN/RBV relapsers; 54.2% were male; 3.9% were Black; ; 12.8% had a history of depression or bipolar disorder; 87.7% had baseline HCV RNA levels of at least 800,000 IU/mL; 17.9% had portal fibrosis (F2) and 14.0% had bridging fibrosis (F3).
Slovenian: Zdravljeni preiskovanci (N = 179) so bili mediano stari 57 let (razpon: od 26 do 70); 35,2 % jih predhodno ni imelo odziva na pegIFN/RBV; 28,5 % jih je predhodno imelo delen odziv na pegIFN/RBV in 36,3 % jih je predhodno imelo recidiv ob pegIFN/RBV; 54,2 % je bilo moških; 3,9 % je bilo črncev; 12,8 % jih je imelo v anamnezi depresijo ali bipolarno motnjo; 87,7 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj 800.000 i. e./ml; 17,9 % jih je imelo portalno fibrozo (F2) in 14,0 % jih je imelo fibrozo z mostiči (F3).
English: 5 mg single dose
Slovenian: Posamezni odmerek 5 mg
English: No dose adjustment of dasabuvir is required in patients with mild hepatic impairment (Child-Pugh A).
Slovenian: Bolnikom z blago okvaro jeter (Child-Pugh A) odmerkov dasabuvirja ni treba prilagoditi.
English: HCV Genotype 1a dasabuvir and ombitasvir/paritaprevir/ritonavir with RBV
Slovenian: HCV Genotip 1a dasabuvir in ombitasvir/paritaprevir/ritonavir Z RBV
English: Stop taking Exviera and talk to your doctor or get medical help immediately if any of the following occur:
Slovenian: Prenehajte z jemanjem zdravila Exviera in se pogovorite z zdravnikom ali si nemudoma priskrbite zdravniško pomoč, če se pojavi kaj od naslednjega: Neželeni učinki, ki se lahko pojavijo pri jemanju zdravila Exviera z ombitasvirjem/paritaprevirjem/ritonavirjem z ali brez ribavirina:
English: Arm B: dasabuvir and ombitasvir/paritaprevir/ritonavir
Slovenian: Skupina B: dasabuvir in ombitasvir/paritaprevir/ritonavir
English: Genotype 1a, without cirrhosis dasabuvir + ombitasvir/paritaprevir/ritonavir + ribavirin*
Slovenian: genotip 1a, brez ciroze dasabuvir + ombitasvir/paritaprevir/ritonavir + ribavirin
English: Mechanism: OATP1B1 inhibition by paritaprevir.
Slovenian: OATP1B1 s paritaprevirjem.
English: Arm A: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV (12 weeks)
Slovenian: Skupina A: dasabuvir in ombitasvir/paritaprevir/ritonavir + RBV (12 tednov)
English: Trial
Slovenian: Preskušanje
English: St. John's Wort (hypericum perforatum)
Slovenian: ZDRAVILA RASTLINSKEGA IZVORA šentjanževka (hypericum perforatum)
English: Mechanism: CYP3A4 inhibition by ritonavir.
Slovenian: Učinek na sirolimus je posledica CYP3A4 inhibicije z ritonavirjem.
English: ↔ nor ethindrone
Slovenian: ↔ tenofovir
English: SVR12 for genotype 1-infected treatment-naïve subjects in SAPPHIRE-I
Slovenian: Preglednica 7: SVR12 pri še nezdravljenih preiskovancih, okuženih z genotipom 1, v preskušanju SAPPHIRE-I
English: IMMUNOSUPPRESSANTS Ciclosporin
Slovenian: ANTIDEPRESIVI escitalopram
English: Refer to the Summary of Product Characteristics for ribavirin for additional information.
Slovenian: Za dodatne informacije glejte povzetek glavnih značilnosti zdravila za ribavirin.
English: See Table 2 for guidance regarding potential drug interactions and dosing recommendations for dasabuvir administered with ombitasvir/paritaprevir/ritonavir.
Slovenian: Za smernice o možnih medsebojnih delovanjih zdravil in priporočila za odmerjanje dasabuvirja, uporabljenega s kombinacijo ombitasvir/paritaprevir/ritonavir, glejte preglednico 2.
English: IRON CHELATORS Deferasirox dasabu vir + ombitas vir/parit aprevir/ ritonavi r
Slovenian: KELATORJI ŽELEZA deferasiroks dasabuvir ombitasvir/ paritaprevi r/ritonavir
English: AbbVie B.V. Tel: +31 (0)88 322 2843
Slovenian: Tel: +31 (0)88 322 2843
English: For contra-indications with ombitasvir/ paritaprevir /ritonavir refer to the Summary of Product Characteristics.
Slovenian: Za kontraindikacije s kombinacijo ombitasvir/paritaprevir/ritonavir glejte povzetek glavnih značilnosti zdravila za ombitasvir/paritaprevir/ritonavir.
English: dasabuvir and ombitasvir/paritaprevir/ritonavir for 8 weeks Treated subjects (N=166) had a median age of 53 years (range: 22 to 82); 56.6% were female; 3.0% were Asian; 0.6% were Black; 7.2% had baseline HCV RNA levels of at least 6,000,000 IU per mL;
Slovenian: Zdravljeni preiskovanci (N=166) so bili mediano stari 53 let (razpon: od 22 do 82); 56,6 % je bilo žensk; 3,0 % je bilo Azijcev; 0,6 % je bilo črncev; 7,2 % jih je imelo izhodiščno koncentracijo HCV
English: They are always taken with another antiviral medicine containing ombitasvir/paritaprevir/ritonavir.
Slovenian: Vedno se jemljejo skupaj z drugim protivirusnim zdravilom, ki vsebuje kombinacijo ombitasvirja/paritaprevirja/ritonavirja.
English: Hepatic impairment
Slovenian: DIURETIKI furosemid
English: Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Slovenian: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
English: Cyclobenzap rine 5 mg single dose
Slovenian: dasabuvir ombitasvir paritaprevir sirolimus 0,5 mg enkratni odmerek5
English: Lansoprazole Mechanism: CYP2C19 induction by ritonavir.
Slovenian: ↔ dasabuvir ↔ ombitasvir ↔ paritaprevir esomeprazol lansoprazol Mehanizem: Indukcija CYP2C19 z ritonavirjem.
English: Dose normalized cyclosporine ratios are shown for interaction with dasabuvir + ombitasvir/paritaprevir/ritonavir.
Slovenian: Za odmerek normalizirana razmerja ciklosporina so prikazana za medsebojno delovanje z dasabuvirjem + kombinacijo ombitasvir/paritaprevir/ritonavir.
English: buprenorphin e/ naloxone 4-24 mg/16 mg once daily8
Slovenian: 4-24 mg/1-6 mg enkrat na dan8
English: Interactions between dasabuvir with ombitasvir/paritaprevir/ritonavir and other medicinal products
Slovenian: Preglednica 2: Medsebojna delovanja z drugimi zdravili med uporabo dasabuvirja s kombinacijo ombitasvir/paritaprevir/ritonavir
English: Use with statins
Slovenian: Uporaba s statini Rosuvastatin
English: Extreme caution must be taken to avoid pregnancy in female patients and female partners of male patients when dasabuvir is used with ribavirin.
Slovenian: Če je dasabuvir uporabljen z ribavirinom, je potrebna skrajna previdnost, da bi preprečili nosečnost bolnic in partnerk bolnikov.
English: Ciclosporin 100 mg dosed alone and 30 mg administered with dasabuvir + ombitasvir/paritaprevir/ritonavir.
Slovenian: Ciklosporin 100 mg, uporabljen sam, ali 30 mg skupaj z dasabuvirjem + kombinacijo ombitasvir/paritaprevir/ritonavir.
English: Atazanavir/ ritonavir 300/100 mg once daily
Slovenian: AUC Ctrough Klinične opombe atazanavir 300 mg enkrat na dan (dan ob istem času)
English: MEDICINAL PRODUCTS USED IN MULTIPLE SCLEROSIS Teriflunomid e dasabu vir +
Slovenian: ZDRAVILA, KI SE UPORABLJAJO PRI ZDRAVLJENJU MULTIPLE SKLEROZE teriflunomid dasabuvir ombitasvir/ paritaprevi r/ritonavir
English: ↑ norgestrel ↑ nor elgestromin e
Slovenian: norgestrel norelgestromi n dasabuvir
English: Reduce pravastatin dose by 50%.
Slovenian: NP Zmanjšajte odmerek pravastatina za
English: The effect on rilpivirine exposures was similar to that observed when rilpivirine was administered in the morning with food with dasabuvir + ombitasvir/paritaprevir/ritonavir.
Slovenian: če je bil rilpivirin uporabljen zjutraj s hrano z dasabuvirjem + kombinacijo ombitasvir/paritaprevir/ritonavir.
English: Treatment outcome dasabuvir and ombitasvir/paritaprevir/ritonavir for 12 weeks With RBV
Slovenian: Izid zdravljenja dasabuvir in ombitasvir/paritaprevir/ritonavir 12 tednov Z RBV
English: Transient elevations in total bilirubin >3 x ULN (mostly indirect) occurred in 17 (27.0%) subjects; 15 of these subjects were receiving atazanavir.
Slovenian: Bolniki, sočasno okuženi s HIV in HCV Celotne varnostne značilnosti pri preiskovancih sočasno okuženih s HCV in HIV-1 so bile podobne kot so jih opažali pri preiskovancih, okuženih samo s HCV. Prehodna zvišanja celokupnega bilirubina (v glavnem indirektnega) na > 3-kratno ZNM so se pojavila pri 17 (27,0 %) preiskovancih; 15 teh preiskovancev je prejemalo atazanavir.
English: Efavirenz/ emtricitabine / tenofovir disoproxil fumarate mg once daily
Slovenian: efavirenz/emtricit abin/tenofovirijev dizoproksilfumar at
English: No dose adjustment is necessary for emtricitabine/tenofovir and dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Slovenian: Prilagoditev odmerka ni potrebna za emtricitabin/tenof ovir in kombinacijo dasabuvir + ombitasvir/paritap revir/ritonavir.
English: Pravastatin 10 mg once daily
Slovenian: 10 mg enkrat na dan
English: Mechanism: CYP2C19 induction by ritonavir dasabu vir +
Slovenian: Mehanizem: Indukcija CYP2C19 z ritonavirjem dasabuvir ombitasvir/ paritaprevi r/ritonavir
English: to thin the blood
Slovenian: (ODGOVORNI) ZA SPROŠČANJE SERIJ
English: Treatment duration 12 weeks
Slovenian: Trajanje zdravljenja
English: Refer to the Summary of Product Characteristics of the medicinal products that are used in combination with dasabuvir.
Slovenian: uporabljenih v kombinaciji z dasabuvirjem.
English: Duloxetine 60 mg single dose dasabu vir + ombitas vir/parit aprevir/ ritonavi r duloxetine
Slovenian: dasabuvir ombitasvir paritaprevir duloksetin Posamezen odmerek 60 mg dasabuvir ombitasvir/ paritaprevi r/ritonavir duloksetin
English: Treated subjects (N=380) had a median age of 58 years (range: 21 to 71); 42.1% were treatment-naïve, 36.1% were prior pegIFN/RBV null responders; 8.2% were prior pegIFN/RBV partial responders, 13.7% were prior pegIFN/RBV relapsers; 70.3% were male; 3.2% were Black; 14.7% had platelet counts of less than 90 x 109/L; 49.7% had albumin less than 40 g/L; 86.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 24.7% had a history of depression or bipolar disorder; 68.7% had HCV genotype 1a infection, 31.3% had HCV genotype 1b infection.
Slovenian: Zdravljeni preiskovanci (N = 380) so bili mediano stari 58 let (razpon: od 21 do 71); 42,1 % jih še ni bilo zdravljenih, 36,1 % jih predhodno ni imelo odziva na pegIFN/RBV; 8,2 % jih je predhodno imelo delen odziv na pegIFN/RBV in 13,7 % jih je predhodno imelo recidiv ob pegIFN/RBV; 70,3 % je bilo moških; 3,2 % je bilo črncev; 14,7 % jih je imelo število trombocitov manj kot 90 x 109/l; 49,7 % jih je imelo albumin manj kot 40 g/l; 86,1 % jih je imelo izhodiščno koncentracijo HCV RNA vsaj
English: Refer to the Summary of Product Characteristics of ombitasvir/paritaprevir/ritonavir for its pharmacological properties.
Slovenian: Za njegove farmakološke lastnosti glejte povzetek glavnih značilnosti zdravila za ombitasvir/paritaprevir/ritonavir.
English: No dose adjustment of dasabuvir is required for patients with mild, moderate, or severe renal impairment or end-stage-renal disease on dialysis (see section 5.2).
Slovenian: Bolnikom z blago, zmerno ali hudo okvaro ledvic ali bolnikom s končno ledvično odpovedjo, ki so na dializi, odmerkov dasabuvirja ni treba prilagoditi (glejte poglavje 5.2).
English: No subjects with HCV genotype 1b infection experienced on-treatment virologic failure and one subject with HCV genotype 1b infection experienced relapse.
Slovenian: Virusna neodzivnost med zdravljenjem se ni pojavila pri nobenem preiskovancu, okuženem s HCV genotipa 1b, recidiv pa se je pojavil pri enem takšnem preiskovancu.
English: The SVR12 rates in HCV/HIV-1 co-infected subjects were thus consistent with SVR12 rates in the phase 3 trials of HCV mono-infected subjects.
Slovenian: Deleži SVR12 pri preiskovancih, sočasno okuženih s HCV/HIV-1, so se skladali z deleži SVR12,
English: Dose normalized tacrolimus ratios are shown for interaction with dasabuvir + ombitasvir/paritaprevir/ritonavir.
Slovenian: Za odmerek normalizirana razmerja takrolimusa so prikazana za medsebojno delovanje z dasabuvirjem + kombinacijo ombitasvir/paritaprevir/ritonavir.
English: NA No dose adjustment required for diazepam; increase dose if clinically indicated.
Slovenian: povečajte odmerek, če je klinično indicirano.
English: Caution should be used when sulfasalazine is co-administered with dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Slovenian: Previdnost je potrebna, ko se sulfasalazin daje sočasno z dasabuvirjem + ombitasvir/paritap revir/ritonavir.
English: SVR12 for genotype 1b-infected treatment-naïve subjects in PEARL III
Slovenian: Preglednica 8: SVR12 pri še nezdravljenih preiskovancih, okuženih z genotipom 1b, v preskušanju PEARL III
English: CYP3A4 inhibition by ritonavir.
Slovenian: Zavrtje CYP3A4 z ritonavirjem.
English: SVR12 for genotype 1a-infected treatment-naïve subjects in PEARL IV
Slovenian: Preglednica 9: SVR12 pri še nezdravljenih preiskovancih, okuženih z genotipom 1a, v preskušanju PEARL IV
English: No dose adjustment is necessary for norethindrone or dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Slovenian: Prilagoditev odmerka ni potrebna za noretindron ali kombinacijo dasabuvir + ombitasvir/paritap revir/ritonavir
English: • If you get any side effects, talk to your doctor or pharmacist.
Slovenian: - Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom.
English: Mechanism: UGT1A1 inhibition by paritaprevir, ombitasvir and dasabuvir.
Slovenian: Zavrtje UGT1A1 s paritaprevirjem, ombitasvirjem in dasabuvirjem.
English: • Serious allergic reactions, signs may include: o Difficulty breathing or swallowing o Dizziness or light-headedness, which may be due to low blood pressure o Swelling of the face, lips, tongue or throat o Rash and itching of the skin
Slovenian: • vrtoglavica ali omotica, ki je lahko posledica nizkega krvnega tlaka
English: Medicinal products that inhibit CYP2C8
Slovenian: Možnost vpliva drugih zdravil na farmakokinetiko dasabuvirja Zdravila, ki zavirajo CYP2C8
English: Metabolism and nutrition disorders Uncommon Dehydration Psychiatric disorders Very common Insomnia Gastrointestinal disorders Very common Nausea, Diarrhoea Common
Slovenian: Neznana pogostnost dekompenzacija jeter in okvara jeter dekompenzacija jeter in okvara jeter Bolezni kože in podkožja
English: Pooled efficacy analysis
Slovenian: UČINKOVITO UPORABO ZDRAVILA
English: Treatment outcome dasabuvir and ombitasvir/paritaprevir/ritonavir with RBV 12 weeks
Slovenian: Izid zdravljenja dasabuvir in ombitasvir/paritaprevir/ritonavir z RBV 12 tednov
English: Breastfeeding
Slovenian: amlodipin
English: Atazanavir must be administered at dasabuvir ombitasvir
Slovenian: ↔ atazanavir dasabuvir
English: Concomitant use of tacrolimus with dasabuvir and ombitasvir/paritaprevir/ ritonavir is not recommended unless the benefits outweigh dasabuvir ombitasvir
Slovenian: Sočasna uporaba sirolimusa z dasabuvirjem + kombinacijo ombitasvir/paritap revir/ritonavir ni priporočljiva,
English: dasabuvir and ombitasvir/paritaprevir/ritonavir without ribavirin or with weight-based ribavirin for 12 weeks
Slovenian: Zdravljenje: dasabuvir in ombitasvir/paritaprevir/ritonavir brez ribavirina ali z ribavirinom, odmerjenim glede na telesno maso, 12 tednov
English: Methadone
Slovenian: ↓ metformin
English: NA Concomitant use is contraindicated (see the Summary of Product Characteristics for
Slovenian: Sočasna uporaba je kontraindicirana (glejte poglavje imatinib
English: ↑ hydrocod one
Slovenian: ↑ hidrokodon 1,27
English: 300 mg single dose itonavir ombitasvir/paritaprevir/ ritonavir.
Slovenian: Posamezni odmerek 300 mg dasabuvir ombitasvir/ paritaprevi r/ ritonavir paracetamol
English: Rare
Slovenian: Recidiv
English: A temporary suspension of pitavastatin/fluvastatin is recommended for the duration of treatment with ombitasvir/paritaprevir/ritonavir.
Slovenian: V času zdravljenja s kombinacijo ombitasvir/paritaprevir/ritonavir je priporočljivo začasno opustiti suspenzijo pitavastatina/fluvastatina.
English: dasabuvir and ombitasvir/paritaprevir/ritonavir with weight-based ribavirin for 12 or 24 weeks
Slovenian: Zdravljenje: dasabuvir in ombitasvir/paritaprevir/ritonavir z ribavirinom, odmerjenim glede na telesno maso, 12 ali 24 tednov
English: Mechanism: CYP3A4 induction by carbamazepi ne.
Slovenian: Mehanizem: Indukcija CYP3A4 s šentjanževko.
English: For interactions with ombitasvir/ paritaprevir /ritonavir refer to the Summary of Product Characteristics.
Slovenian: Za interakcije z ombitasvirjem/paritaprevirjem/ritonavirjem glejte povzetek glavnih značilnosti zdravila.
English: Skin and subcutaneous tissue disorders Very common Pruritus Common
Slovenian: Splošne težave in spremembe na mestu aplikacije Zelo pogosti astenija utrujenost
English: Prior pegIFN/RBV null responder Prior pegIFN/RBV partial responder Prior pegIFN/RBV relapser Outcome for subjects without SVR12 On-treatment VF
Slovenian: Celotni SVR12 HCV genotip 1a Predhodno brez odziva na pegIFN/RBV Predhodno delen odziv na pegIFN/RBV Predhodno recidiv ob pegIFN/RBV HCV genotip 1b Predhodno brez odziva na pegIFN/RBV Predhodno delen odziv na pegIFN/RBV Predhodno recidiv ob pegIFN/RBV Izid pri preiskovancih brez SVR12 VN med zdravljenjem Recidiv Drugo
English: Mechanism: CYP3A inhibition by ritonavir.
Slovenian: Zavrtje CYP3A z ritonavirjem.
English: No increase in incidence of ALT elevations was observed with other types of systemic oestrogens commonly used for hormone replacement therapy (e.g., oestradiol and conjugated oestrogens).
Slovenian: Z drugimi vrstami sistemskih estrogenov, ki se pogosto uporabljajo za hormonsko nadomestno zdravljenje (npr. z estradiolom in konjugiranimi estrogeni), niso opažali večje incidence zvišanj ALT. Zvišanja ALT so bila praviloma asimptomatska, so se po navadi pojavila v prvih 4 tednih zdravljenja (povprečni čas 20 dni, razpon od
English: Dasabuvir is administered with ombitasvir/paritaprevir/ritonavir.
Slovenian: Dasabuvir se uporablja s kombinacijo ombitasvir/paritaprevir/ritonavir.
English: paritaprevir the same time as dasabuvir +ombitasvir/paritaprevi r/ritonavir.
Slovenian: Mehanizem: ni znan dasabuvir ombitasvir/ paritaprevi r/ritonavir.
English: dasabuvir and ombitasvir/paritaprevir /ritonavir
Slovenian: dasabuvir in ombitasvir/paritaprevir/ritonavir
English: dasabuvir and ombitasvir/paritaprevir/ritonavir
Slovenian: dasabuvir in ombitasvir/paritaprevir /ritonavir
English: 800/160 mg twice daily dasabu vir +
Slovenian: 800/160 mg dvakrat na dan
English: No dose adjustment is necessary for methadone and dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Slovenian: Prilagoditev odmerka ni potrebna za metadon in kombinacijo dasabuvir + ombitasvir/paritap revir/ritonavir.
English: Mechanism: possibly due to UGT1A1 inhibition by paritaprevir, dasabuvir and ombitasvir and CYP3A4 inhibition by ritonavir dasabuvi r + ombitas vir/parit aprevir/r itonavir dolutegravir
Slovenian: Zavrtje CYP3A4 z ritonavirjem in zavrtje UGT s paritaprevirjem, ombitasvirjem in dasabuvirjem dasabuvir ombitasvir/ paritaprevi r/ritonavir
English: paritaprevir the risks (see section
Slovenian: paritaprevir razen kadar koristi prevladajo nad tveganji (glejte poglavje
English: ombitas vir/parit aprevir/r itonavir atazanavir dasabuvir ombitasvir paritaprevir
Slovenian: ombitasvir ↑ paritaprevir atazanavir/ ritonavir dasabuvir ombitasvir/ paritaprevi r/ritonavir
English: ↓ dasabuvir ↓ paritaprevir ↓ ombitasvir
Slovenian: ↔ dasabuvir ↔ ombitasvir